APLM Apollomics highlights oncology pipeline progress and upcoming clinical trial milestones in its latest quarterly earnings report TWO Two posts sharp 30 percent Q4 2025 EPS miss shares remain flat after earnings release CRBP Corbus posts narrower than expected Q4 2025 loss yet shares dip 157 percent in todays trading